BioNTech SE (BNTX)
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a clinically meaningful overall survival benefit in a certain form of lung cancer compared with standard treatment.
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. BNTX's next-gen anti-CTLA-4 gotistobart and PD-L1xVEGF-A bispecific antibody pumitamig have multiple pivotal trial catalysts, with key data readouts expected at WCLC 2026. COMIRNATY's XFG variant expansion provides near-term revenue, but COVID-19 vaccine sales face competitive and demand headwinds, reflected in lowered 2026 guidance.
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech Q2 Earnings Call Highlights
BioNTech NASDAQ: BNTX reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt out of a shingles vaccine development program.
BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free
BioNTech trades near cash value, implying its advanced oncology pipeline is valued at nearly zero—an opportunity I rate as BUY. BNTX's €16.8B liquidity, $1B buyback, and cost restructuring enable multi-year funding without dilution, reflecting strong management conviction. Key 2026 catalysts include the trastuzumab pamirtecan BLA filing, pivotal Phase 3 oncology readouts, and a binary EPO patent event in September.
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Two experimental drugs showed striking early results against pancreatic cancer
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
